Physician profile
Gary Pisanchyn
NPI 1598712846
$1,586.90
in general payments reported to CMS, 2019-2025
16 companies · $53.71 in 2025
The $53.71 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $202 · 2021: $229 · 2022: $321 · 2023: $307 · 2024: $173 · 2025: $53.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $533.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $312.69 | 2019-2023 | |
| Alcon Vision LLC | $303.58 | 2019-2024 | Rocklatan, Simbrinza |
| Oyster Point Pharma, INC. | $197.95 | 2022-2024 | Tyrvaya, Ryzumvi |
| Allergan, INC. | $122.37 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $118.54 | 2019-2023 | Cequa |
| Bausch & Lomb Americas INC. | $113.42 | 2022-2024 | Vyzulta, Miebo, Xiidra |
| Kala Pharmaceuticals, INC. | $98.36 | 2021-2022 | |
| Amgen INC. | $81.31 | 2024-2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $79.95 | 2019-2021 | |
| Abbvie INC. | $30.83 | 2022 | |
| Omeros Corporation | $27.29 | 2019 | |
| Biotissue Holdings INC. | $25.32 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $24.56 | 2024 | Xdemvy |
| Dompe US, INC. | $19.00 | 2023 | Oxervate |
| Shire North American Group INC | $16.27 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $15.46 | 2024 | Amo Phaco Needle |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Pisanchyn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.